Synthetic antiviral peptides: a new way to develop targeted antiviral drugs

References

• 1. Luo G, Gao SJ. Global health concerns stirred by emerging viral infections. J. Med. Virol. 92(4), 399 (2020).
  Medline CASGoogle Scholar
• 2. Fauci AS, Morens DM. The perpetual challenge of infectious diseases. N. Engl. J. Med. 366(5), 454–461 (2012).
  Medline CASGoogle Scholar
• 3. Graham BS, Sullivan NJ. Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic review-article. Nat. Immunol. 19(1), 20–28 (2018).
  Medline CASGoogle Scholar
• 4. ORGANIZATION WH. COVID-19 weekly epidemiological update. 55, 1–15 (2021).
  Google Scholar
• 5. Souza PFN. Synthetic peptides as promising antiviral molecules. Future Virol. 17(1), 9–11 (2022).
  CASGoogle Scholar
• 6. Souza PFN, Mesquita FP, Amaral JL et al. The human pandemic coronaviruses on the show: the spike glycoprotein as the main actor in the coronaviruses play. Int. J. Biol. Macromol. 179, 1–19 (2021).
  Medline CASGoogle Scholar
• 7. Magalhães ICL, Souza PFN, Marques LEC, Girão NM, Araújo FMC, Guedes MIF. New insights into the recombinant proteins and monoclonal antibodies employed to immunodiagnosis and control of Zika virus infection: a review. Int. J. Biol. Macromol. 200(September 2021), 139–150 (2022).
  Medline CASGoogle Scholar
• 8. De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29(3), 695–747 (2016).
  MedlineGoogle Scholar
• 9. Tompa DR, Immanuel A, Srikanth S, Kadhirvel S. Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs. Int. J. Biol. Macromol. 172, 524–541 (2021).
  Medline CASGoogle Scholar
• 10. Lou Z, Sun Y, Rao Z. Current progress in antiviral strategies. Trends Pharmacol. Sci. 35(2), 86–102 (2014).
  Medline CASGoogle Scholar
• 11. Agarwal G, Gabrani R. Antiviral peptides: identification and validation. Int. J. Pept. Res. Ther. 27(1), 149–168 (2021).
  Medline CASGoogle Scholar
• 12. Irwin KK, Renzette N, Kowalik TF, Jensen JD. Antiviral drug resistance as an adaptive process. Virus Evol. 2(1), vew014 (2016).
  MedlineGoogle Scholar
• 13. Charoenkwan P, Anuwongcharoen N, Nantasenamat C, Hasan M, Shoombuatong W. In silico approaches for the prediction and analysis of antiviral peptides: a review. Curr. Pharm. Des. 27(18), 2180–2188 (2021).
  Medline CASGoogle Scholar
• 14. Research, Markets. Peptide therapeutics market – growth, trends, COVID-19 impact, and forecasts (2021–2026) (2021). https://www.researchandmarkets.com/reports/5265155/peptide-therapeutics-market-growth-trends
  Google Scholar
• 15. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorganic Med. Chem. 26(10), 2700–2707 (2018).
  Medline CASGoogle Scholar
• 16. Gentilucci L, De Marco R, Cerisoli L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 16(28), 3185–3203 (2010).
  Medline CASGoogle Scholar
• 17. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 15(1–2), 40–56 (2010).
  Medline CASGoogle Scholar
• 18. Maharani R, Muhajir MI. An overview of chemical synthesis of antiviral peptides. Sci. Eng. Heal. Stud. 21010003 (2021).
  Google Scholar
• 19. Sala A, Ardizzoni A, Ciociola T et al. Antiviral activity of synthetic peptides derived from physiological proteins. Intervirology. 61(4), 166–173 (2019).
  Google Scholar
• 20. Ali R, Rani R, Kumar S. New peptide based therapeutic approaches. Adv. Protein Chem. 14(3), 1–8 (2014).
  Google Scholar
• 21. Lata S, Sharma BK, Raghava G. Analysis and prediction of antibacterial peptides. (2007).http://www.imtech.res.in/raghava/antibp/
  Google Scholar
• 22. Lata S, Mishra NK, Raghava GP. AntiBP2: improved version of antibacterial peptide prediction. BMC Bioinformatics. 11(Suppl. 1), S19 (2010).
  MedlineGoogle Scholar
• 23. Torrent M, Di Tommaso P, Pulido D et al. AMPA: an automated web server for prediction of protein antimicrobial regions. Bioinformatics. 28(1), 130–131 (2012).
  Medline CASGoogle Scholar
• 24. Sharma A, Gupta P, Kumar R, Bhardwaj A. dPABBs: a novel in silico approach for predicting and designing anti-biofilm peptides. Sci. Rep. 6(1), 21839 (2016).
  Medline CASGoogle Scholar
• 25. Gautam A, Chaudhary K, Kumar R, Raghava GPS. Computer-aided virtual screening and designing of cell-penetrating peptides. Humana Press, NY, USA, 59–69 (2015).
  Google Scholar
• 26. Pirtskhalava M, Gabrielian A, Cruz P et al. DBAASP v.2: an enhanced database of structure and antimicrobial/cytotoxic activity of natural and synthetic peptides. Nucleic Acids Res. 44(D1), D1104–D1112 (2016).
  Medline CASGoogle Scholar
• 27. Waghu FH, Barai RS, Gurung P, Idicula-Thomas S. CAMP _R3: a database on sequences, structures and signatures of antimicrobial peptides: table 1. Nucleic Acids Res. 44(D1), D1094–D1097 (2016).
  Medline CASGoogle Scholar
• 28. Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 44(D1), D1087–D1093 (2016).
  Medline CASGoogle Scholar
• 29. Niarchou A, Alexandridou A, Athanasiadis E, Spyrou G. C-PAmP: large scale analysis and database construction containing high scoring computationally predicted antimicrobial peptides for all the available plant species. PLoS ONE 8(11), e79728 (2013).
  Medline CASGoogle Scholar
• 30. Xiao X, Wang P, Lin WZ, Jia JH, Chou KC. iAMP-2L: a two-level multi-label classifier for identifying antimicrobial peptides and their functional types. Anal. Biochem. 436(2), 168–177 (2013).
  Medline CASGoogle Scholar
• 31. Joseph S, Karnik S, Nilawe P, Jayaraman VK, Idicula-Thomas S. ClassAMP: a prediction tool for classification of antimicrobial peptides. IEEE/ACM Trans. Comput. Biol. Bioinforma. 9(5), 1535–1538 (2012).
  MedlineGoogle Scholar
• 32. Porto WF, Pires ÁS, Franco OL. CS-AMPPred: an updated SVM model for antimicrobial activity prediction in cysteine-stabilized peptides. PLoS ONE 7(12), e51444 (2012).
  Medline CASGoogle Scholar
• 33. Meher PK, Sahu TK, Rao AR. Prediction of donor splice sites using random forest with a new sequence encoding approach. BioData Min. 9(1), 4 (2016).
  MedlineGoogle Scholar
• 34. Gasteiger E, Hoogland C, Gattiker A et al. Protein identification and analysis tools on the ExPASy server. In: The Proteomics Protocols Handbook. Humana Press, NJ, USA, 571–607 (2005).
  Google Scholar
• 35. Sharma A, Singla D, Rashid M, Raghava GP. Designing of peptides with desired half-life in intestine-like environment. BMC Bioinformatics 15(1), 282 (2014).
  MedlineGoogle Scholar
• 36. Boswell PG, Schellenberg JR, Carr PW, Cohen JD, Hegeman AD. A study on retention “projection” as a supplementary means for compound identification by liquid chromatography–mass spectrometry capable of predicting retention with different gradients, flow rates, and instruments. J. Chromatogr. A 1218(38), 6732–6741 (2011).
  Medline CASGoogle Scholar
• 37. Mól A, Castro M, Fontes W. A web application to create high quality peptide helical wheel and net projections. 1–7 (2016). http://lbqp.unb.br/NetWheels/
  Google Scholar
• 38. Whitmore L, Wallace BA. Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases (2007). http://www.interscience.wiley.com
  Google Scholar
• 39. Molero-Abraham M, Glutting JP, Flower DR, Lafuente EM, Reche PA. EPIPOX: immunoinformatic characterization of the shared T-cell epitome between variola virus and related pathogenic orthopoxviruses. J. Immunol. Res. 2015, 1–11 (2015).
  Google Scholar
• 40. Chaudhary K, Kumar R, Singh S et al. A web server and mobile app for computing hemolytic potency of peptides. Sci. Rep. 6(1), 22843 (2016).
  Medline CASGoogle Scholar
• 41. Gupta S, Kapoor P, Chaudhary K et al. In Silico approach for predicting toxicity of peptides and proteins. PLoS ONE 8(9), e73957 (2013).
  Medline CASGoogle Scholar
• 42. Tyagi A, Kapoor P, Kumar R, Chaudhary K, Gautam A, Raghava GPS. In silico models for designing and discovering novel anticancer peptides. Sci. Rep. 3(1), 2984 (2013).
  MedlineGoogle Scholar
• 43. Thakur N, Qureshi A, Kumar M. AVPpred: collection and prediction of highly effective antiviral peptides. Nucleic Acids Res. 40(W1), W199–W204 (2012).
  Medline CASGoogle Scholar
• 44. Kumar M, Gromiha MM, Raghava GPS. SVM based prediction of RNA-binding proteins using binding residues and evolutionary information. J. Mol. Recognit. 24(2), 303–313 (2011).
  Medline CASGoogle Scholar
• 45. Shen Y, Maupetit J, Derreumaux P, Tufféry P. Improved PEP-FOLD approach for peptide and miniprotein structure prediction. J. Chem. Theory Comput. 10(10), 4745–4758 (2014).
  Medline CASGoogle Scholar
• 46. Hrobowski YM, Garry RF, Michael SF. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol. J. 2(1), 1–10 (2005).
  MedlineGoogle Scholar
• 47. Schüller A, Yin Z, Chia CSB et al. Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease. Antiviral Res. 92(1), 96–101 (2011).
  Medline CASGoogle Scholar
• 48. Zheng BJ, Guan Y, He ML et al. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coron. Related papers therapies for coronaviruses. Part I of II-viral entry inhibitors receptor-binding domain of SARS-CoV spike protein induction. Antivir. Ther. 10(3), 393–403 (2005).
  Medline CASGoogle Scholar
• 49. Gan YR, Huang H, Huang YD et al. Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase. Peptides 27(4), 622–625 (2006).
  Medline CASGoogle Scholar
• 50. Day CW, Baric R, Cai SX et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology 395(2), 210–222 (2009).
  Medline CASGoogle Scholar
• 51. Chuck CP, Ke ZH, Chen C, Wan DCC, Chow HF, Wong KB. Profiling of substrate-specificity and rational design of broad-spectrum peptidomimetic inhibitors for main proteases of coronaviruses. Hong Kong Med. J. 20(Suppl. 4), 1–12 (2014).
  Google Scholar
• 52. Souza PFN, Amaral JL, Bezerra LP et al. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor. J. Biomol. Struct. Dyn. 2, 1–14 (2021).
  Google Scholar
• 53. Ling R, Dai Y, Huang B et al. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2. Peptides 130, 170328 (2020).
  Medline CASGoogle Scholar
• 54. Xia S, Liu M, Wang C et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30(4), 343–355 (2020).
  Medline CASGoogle Scholar
• 55. Zhao H, Zhou J, Zhang K et al. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci. Rep. 6, 1–12 (2016).
  MedlineGoogle Scholar
• 56. Ghanem A, Mayer D, Chase G et al. Peptide-mediated interference with influenza A virus polymerase. J. Virol. 81(14), 7801–7804 (2007).
  Medline CASGoogle Scholar
• 57. Li C, Ba Q, Wu A, Zhang H, Deng T, Jiang T. A peptide derived from the C-terminus of PB1 inhibits influenza virus replication by interfering with viral polymerase assembly. FEBS J. 280(4), 1139–1149 (2013).
  Medline CASGoogle Scholar
• 58. Wunderlich K, Mayer D, Ranadheera C et al. Identification of a PA-binding peptide with inhibitory activity against influenza A and B virus replication. PLoS One. 4(10), 1–10 (2009).
  Google Scholar
• 59. Hoffmann J, Schneider C, Heinbockel L, Brandenburg K, Reimer R, Gabriel G. A new class of synthetic anti-lipopolysaccharide peptides inhibits influenza A virus replication by blocking cellular attachment. Antiviral Res. 104(1), 23–33 (2014).
  MedlineGoogle Scholar
• 60. Owen SM, Rudolph DL, Wang W et al. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 20(11), 1157–1165 (2004).
  Medline CASGoogle Scholar
• 61. Mzoughi O, Teixido M, Planès R et al. Trimeric heptad repeat synthetic peptides HR1 and HR2 efficiently inhibit HIV-1 entry. Biosci. Rep. 39(9), BSR20192196 (2019).
  MedlineGoogle Scholar
• 62. Fung HB, Guo Y. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin. Ther. 26(3), 352–378 (2004).
  Medline CASGoogle Scholar
• 63. Zhao D, Zhang L, Han K et al. Peptide inhibitors of tembusu virus infection derived from the envelope protein. Vet. Microbiol. 245, 108708 (2020).
  Medline CASGoogle Scholar
• 64. Yu Y, Deng YQ, Zou P et al. A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nat. Commun. 8(1), 1–12 (2017).
  MedlineGoogle Scholar
• 65. Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR. Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection radeekorn akkarawongsa. Antimicrob. Agents Chemother. 53(3), 987–996 (2009).
  Medline CASGoogle Scholar
• 66. Curreli F, Victor SMB, Ahmed S et al. Laboratory stapled peptides based on human angiotensin-converting. MBio. 11(6), 1–13 (2020).
  Google Scholar
• 67. Larue RC, Xing E, Kenney AD et al. Rationally designed ACE2-derived peptides inhibit SARS-CoV-2. Bioconjug. Chem. 32(1), 215–223 (2021).
  Medline CASGoogle Scholar
• 68. Souza PFN, Lopes FES, Amaral JL, Freitas CDT, Oliveira JTA. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. Int. J. Biol. Macromol. 164, 66–76 (2020).
  Medline CASGoogle Scholar
• 69. Amaral JL, Oliveira JTA, Lopes FES et al. Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease (2021). https://www.tandfonline.com/doi/abs/10.1080/07391102.2021.1920464
  Google Scholar
• 70. Souza PFN, Mesquita FP, Amaral JL et al. Neutralizing effect of synthetic peptides toward SARS-CoV-2. ACS Omega. 7(1), 16222–16234 (2022).
  Google Scholar
• 71. Burman R, Yeshak MY, Larsson S, Craik DJ, Rosengren KJ, Göransson U. Distribution of circular proteins in plants: large-scale mapping of cyclotides in the Violaceae. Front. Plant Sci. 6, 855 (2015).
  MedlineGoogle Scholar
• 72. Henriques ST, Craik DJ. Cyclotides as templates in drug design. Drug Discov. Today 15(1–2), 57–64 (2010).
  Medline CASGoogle Scholar
• 73. Ireland DC, Wang CKL, Wilson JA, Gustafson KR, Craik DJ. Cyclotides as natural anti-HIV agents. Biopolym. - Pept. Sci. Sect. 90(1), 51–60 (2008).
  Medline CASGoogle Scholar
• 74. Gao Y, Cui T, Lam Y. Synthesis and disulfide bond connectivity-activity studies of a kalata B1-inspired cyclopeptide against dengue NS2B-NS3 protease. Bioorganic Med. Chem. 18(3), 1331–1336 (2010).
  Medline CASGoogle Scholar
• 75. Daly NL, Gustafson KR, Craik DJ. The role of the cyclic peptide backbone in the anti-HIV activity of the cyclotide kalata B1. FEBS Lett. 574(1–3), 69–72 (2004).
  Medline CASGoogle Scholar
• 76. Gustafson KR, Sowder RC, Henderson LE et al. Circulins A and B novel HIV-inhibitory macrocyclic peptides from the tropical tree Chassalia parvifofial. J. Am. Chem. Soc. 116, 9337–9338 (1994).
  CASGoogle Scholar
• 77. Ngai PHK, Ng TB. Phaseococcin, an antifungal protein with antiproliferative and anti-HIV-1 reverse transcriptase activities from small scarlet runner beans. Biochem. Cell Biol. 83(2), 212–220 (2005).
  Medline CASGoogle Scholar
• 78. Jack HW, Tzi BN. Sesquin, a potent defensin-like antimicrobial peptide from ground beans with inhibitory activities toward tumor cells and HIV-1 reverse transcriptase. Peptides 26(7), 1120–1126 (2005).
  MedlineGoogle Scholar
• 79. Filho IC, Cortez DAG, Ueda-Nakamura T, Nakamura CV, Filho BPD. Antiviral activity and mode of action of a peptide isolated from Sorghum bicolor. Phytomedicine 15(3), 202–208 (2008).
  MedlineGoogle Scholar
• 80. Alché LE, Barquero AA, Sanjuan NA, Coto CE. An antiviral principle present in a purified fraction from Melia azedarach L. leaf aqueous extract restrains herpes simplex virus type 1 propagation. Phyther. Res. 16(4), 348–352 (2002).
  Medline CASGoogle Scholar
• 81. Alché LE, Berra A, Veloso MJ, Coto CE. Treatment with meliacine, a plant derived antiviral, prevents the development of herpetic stromal keratitis in mice. J. Med. Virol. 61(4), 474–480 (2000).
  Medline CASGoogle Scholar
• 82. Pen G, Yang N, Teng D, Mao R, Hao Y, Wang J. A review on the use of antimicrobial peptides to combat porcine viruses. Antibiotics 9(11), 1–18 (2020).
  Google Scholar
• 83. Galdiero S, Falanga A, Tarallo R et al. Peptide inhibitors against herpes simplex virus infections. J. Pept. Sci. 19(3), 148–158 (2013).
  Medline CASGoogle Scholar
• 84. Zhang HZ, Zhang H, Kemnitzer W et al. Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors. J. Med. Chem. 49(3), 1198–1201 (2006).
  Medline CASGoogle Scholar
• 85. Albiol Matanic VC, Castilla V. Antiviral activity of antimicrobial cationic peptides against Junin virus and herpes simplex virus. Int. J. Antimicrob. Agents. 23(4), 382–389 (2004).
  MedlineGoogle Scholar
• 86. Monteiro JMC, Oliveira MD, Dias RS et al. The antimicrobial peptide HS-1 inhibits dengue virus infection. Virology 514, 79–87 (2018).
  Medline CASGoogle Scholar
• 87. Yuan L, Zhang S, Wang Y, Li Y, Wang X, Yang Q. Surfactin inhibits membrane fusion during invasion of epithelial cells by enveloped viruses. J. Virol. 92(21), (2018).
  Google Scholar
• 88. Vollenbroich D, Özel M, Vater J, Kamp RM, Pauli G. Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis. Biologicals. 25(3), 289–297 (1997).
  Medline CASGoogle Scholar
• 89. Silva DS, de Castro CC, Silva FS et al. Antiviral activity of a Bacillus sp: p34 peptide against pathogenic viruses of domestic animals. Brazilian J. Microbiol. 45(3), 1089–1094 (2014).
  MedlineGoogle Scholar
• 90. Todorov SD, Wachsman MB, Knoetze H, Meincken M, Dicks LMT. An antibacterial and antiviral peptide produced by Enterococcus mundtii ST4V isolated from soya beans. Int. J. Antimicrob. Agents. 25(6), 508–513 (2005).
  Medline CASGoogle Scholar
• 91. Lee ACL, Harris JL, Khanna KK, Hong JH. A comprehensive review on current advances in peptide drug development and design. Int. J. Mol. Sci. 20(10), 2383 (2019).
  Google Scholar
• 92. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov. Today 20(1), 122–128 (2015).
  Medline CASGoogle Scholar
• 93. Souza PFN, Marques LSM, Oliveira JTA et al. Synthetic antimicrobial peptides: from choice of the best sequences to action mechanisms. Biochimie 175, 132–145 (2020).
  Medline CASGoogle Scholar
• 94. Jaroszewicz W, Morcinek-Orłowska J, Pierzynowska K, Gaffke L, Węgrzyn G. Phage display and other peptide display technologies. FEMS Microbiol. Rev. 46(2), 1–17 (2022).
  Google Scholar
• 95. Kunamneni A, Ogaugwu C, Bradfute S, Durvasula R. Ribosome display technology: applications in disease diagnosis and control. Antibodies (Basel, Switzerland). 9(3), 28 (2020).
  CASGoogle Scholar
• 96. Sokullu E, Gauthier MS, Coulombe B. Discovery of antivirals using phage display. Viruses. 13(6), 16521–16234 (2021).
  Google Scholar
• 97. Hashemi ZS, Zarei M, Fath MK et al. In silico approaches for the design and optimization of interfering peptides against protein–protein interactions. Front. Mol. Biosci. 8, 282 (2021).
  Google Scholar
• 98. Souza PFN, Lopes FES, Amaral JL, Freitas CDT, Oliveira JTA. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor. Int. J. Biol. Macromol. 164, 66–76 (2020).
  Medline CASGoogle Scholar
• 99. Amaral JL, Oliveira JTA, Lopes FES et al. Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease. J. Biomol. Struct. Dyn. 4(1), 1–13 (2021).
  Google Scholar
• 100. Vilas Boas LCP, Campos ML, Berlanda RLA, de Carvalho Neves N, Franco OL. Antiviral peptides as promising therapeutic drugs. Cell. Mol. Life Sci. 76(18), 3525–3542 (2019).
  Medline CASGoogle Scholar
• 101. Chew MF, Poh KS, Poh CL. Peptides as therapeutic agents for dengue virus. Int. J. Med. Sci. 14(13), 1342 (2017).
  Medline CASGoogle Scholar
• 102. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem. Biol. Drug Des. 81(1), 136–147 (2013).
  Medline CASGoogle Scholar
• 103. Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol. Sci. 38(4), 406–424 (2017).
  Medline CASGoogle Scholar
• 104. Maginnis MS. Virus–receptor interactions: the key to cellular invasion. J. Mol. Biol. 430(17), 2590–2611 (2018).
  Medline CASGoogle Scholar
• 105. Salas CE, Badillo-Corona JA, Ramírez-Sotelo G, Oliver-Salvador C. Biologically active and antimicrobial peptides from plants. Biomed Res. Int. 2015, 102129 (2015).
  MedlineGoogle Scholar
• 106. Han S, Zhao G, Wei Z et al. An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade. Peptides. 145(June), 170638 (2021).
  Medline CASGoogle Scholar
• 107. A phase I/II trial to evaluate a peptide vaccine plus ipilimumab in patients with melanoma. https://clinicaltrials.gov/ct2/show/NCT02385669
  Google Scholar
• 108. Cabri W, Cantelmi P, Corbisiero D et al. Therapeutic peptides targeting PPI in clinical development: overview, mechanism of action and perspectives. Front. Mol. Biosci. 8, 565 (2021).
  Google Scholar
• 109. Shabbir W, Tzotzos S, Bedak M et al. Glycosylation-dependent activation of epithelial sodium channel by solnatide. Biochem. Pharmacol. 98(4), 740–753 (2015).
  Medline CASGoogle Scholar
• 110. Pennington MW, Zell B, Bai CJ. Commercial manufacturing of current good manufacturing practice peptides spanning the gamut from neoantigen to commercial large-scale products. Med. Drug Discov. 9, 100071 (2021).
  CASGoogle Scholar
• 111. Buckley ST, Bækdal TA, Vegge A et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci. Transl. Med. 10(468), 7047 (2018).
  Google Scholar
• 112. Zhang T, Chen Z, Tian Y et al. Kilogram-scale synthesis of osteogenic growth peptide (10–14) using a fragment coupling approach. Org. Process Res. Dev. 19(9), 1257–1262 (2015).
  Google Scholar
• 113. Isidro-Llobet A, Kenworthy MN, Mukherjee S et al. Sustainability challenges in peptide synthesis and purification: from R&D to production. J. Org. Chem. 84(8), 4615–4628 (2019).
  Medline CASGoogle Scholar
• 114. Heydari H, Golmohammadi R, Mirnejad R, Tebyanian H, Fasihi-Ramandi M, Moghaddam MM. Antiviral peptides against Coronaviridae family: a review. Peptides 139, 170526 (2021).
  Medline CASGoogle Scholar
• 115. Boas LCPV, Campos ML, Berlanda RLA, de Carvalho Neves N, Franco OL. Antiviral peptides as promising therapeutic drugs. Cell. Mol. Life Sci. 76(18), 3525–3542 (2019).
  MedlineGoogle Scholar
• 116. Bhat ZF, Kumar S, Bhat HF. Bioactive peptides of animal origin: a review. J. Food Sci. Technol. 52(9), 5377–5392 (2015).
  Medline CASGoogle Scholar